…
LadRx Corporation, a biopharmaceutical company, engages in research and development of chemotherapeutic drugs for solid tumors. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer. Further, the company's Linker Activated Drug Release technology platform consists of an organic backbone, as well as develops albumin companion diagnostic to identify patients with cancer. The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Publicly listed on the OTCQB, LadRx Corporation has limited publicly available disclosures about its business operations and strategic plans. Because filings and communications are sparse, major long-term growth drivers are not clearly stated and appear dependent on future corporate developments; investors may find its early-stage, small-cap profile could support upside if management executes and provides more transparent information.
Primary risks include limited disclosure and transparency, low trading liquidity, likely need for external financing, and execution and regulatory uncertainties that could materially affect prospects.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -4.20M | -13.18M | -6.70M | -7.52M | -9.08M |
| Net income | -4.20M | -13.18M | -6.70M | -7.16M | -12.71M |
| Selling general administrative | 4.54M | 5.97M | 6.00M | 7.44M | 8.08M |
| Reconciled depreciation | 0.02M | 0.01M | 0.23M | 0.02M | 0.03M |
| Ebit | -4.56M | -5.98M | -6.83M | -7.86M | -8.25M |
| Ebitda | -4.54M | -5.97M | -6.60M | -7.50M | -7.33M |
| Operating income | -4.56M | -5.98M | -6.83M | -7.86M | -8.25M |
| Interest expense | - | - | - | 0.00M | 1.72M |
| Tax provision | - | 0.00M | 0.00M | 0.00M | 0.00M |
| Interest income | 0.01M | 0.02M | 0.12M | 0.35M | 0.36M |
| Net interest income | 0.01M | 0.02M | 0.12M | 0.35M | -1.36M |
| Income tax expense | - | - | 0.00M | 0.00M | 0.00M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.25M |
| Total operating expenses | 4.56M | 5.98M | 6.83M | 7.86M | 8.50M |
| Total other income expense net | 0.35M | -7.21M | 0.01M | -0.01M | 0.53M |
| Discontinued operations | - | - | - | 0.36M | -3.63M |
| Net income from continuing ops | -4.20M | -13.18M | -6.70M | -7.52M | -9.08M |
| Net income applicable to common shares | -4.76M | -13.35M | -6.70M | -7.16M | -12.71M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 2.25M | 8.73M | 12.06M | 17.26M | 22.93M |
| Other current assets | 0.63M | 1.31M | 1.09M | 1.07M | 0.08M |
| Total liab | 2.22M | 3.95M | 3.19M | 2.05M | 2.56M |
| Total stockholder equity | 0.03M | 4.78M | 8.87M | 15.20M | 20.36M |
| Other current liab | 0.02M | 0.01M | 0.02M | 0.00M | 0.63M |
| Common stock | 0.05M | 0.04M | 0.04M | 0.03M | 0.03M |
| Capital stock | 1.39M | 4.06M | 0.04M | 0.03M | 0.03M |
| Retained earnings | -488.84M | -484.08M | -470.73M | -464.03M | -456.86M |
| Good will | - | - | - | - | 0.00M |
| Other assets | 0.01M | 0.02M | 0.02M | 0.01M | 0.37M |
| Cash | 1.37M | 6.77M | 10.00M | 16.13M | 21.37M |
| Total current liabilities | 2.19M | 3.73M | 2.77M | 2.05M | 2.56M |
| Property plant equipment | 0.24M | 0.43M | 0.62M | 0.04M | 0.04M |
| Total current assets | 2.00M | 8.28M | 11.42M | 17.20M | 22.52M |
| Net tangible assets | -1.32M | 0.75M | 8.87M | 15.20M | 20.36M |
| Net receivables | 0.00M | 0.20M | 0.33M | 0.01M | 0.15M |
| Accounts payable | 0.98M | 1.47M | 1.40M | 0.89M | 1.23M |
| Non currrent assets other | 0.01M | 0.02M | 0.02M | 0.01M | 0.37M |
| Non current assets total | 0.24M | 0.45M | 0.64M | 0.05M | 0.41M |
| Capital lease obligations | 0.23M | 0.42M | 0.60M | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -0.00M | -0.01M | -0.03M | 0.48M | -0.01M |
| Change to liabilities | -0.49M | 0.07M | 0.19M | -0.35M | -2.83M |
| Total cashflows from investing activities | -0.00M | -0.01M | -0.03M | 0.48M | -0.01M |
| Net borrowings | - | - | - | - | -9.99M |
| Total cash from financing activities | -0.56M | 9.08M | 0.04M | 0.04M | -5.25M |
| Change to operating activities | -0.34M | 0.60M | -0.19M | 0.32M | -6.39M |
| Net income | -4.20M | -13.18M | -6.70M | -7.16M | -12.71M |
| Change in cash | -5.39M | -3.23M | -6.13M | -5.24M | -16.12M |
| Begin period cash flow | 6.77M | 10.00M | 16.13M | 21.37M | 37.50M |
| End period cash flow | 1.37M | 6.77M | 10.00M | 16.13M | 21.37M |
| Total cash from operating activities | -4.83M | -12.31M | -6.14M | -5.72M | -10.87M |
| Issuance of capital stock | 0.00M | 9.18M | - | 0.00M | 6.51M |
| Depreciation | 0.20M | 0.20M | 0.23M | 0.02M | 0.03M |
| Other cashflows from investing activities | - | - | - | 0.50M | 0.50M |
| Dividends paid | 0.56M | 0.17M | 0.17M | 0.17M | 0.17M |
| Change to account receivables | - | - | - | 0.14M | 7.36M |
| Other cashflows from financing activities | - | - | - | - | -1.77M |
| Change to netincome | 0.01M | 0.01M | 0.33M | 1.31M | 2.53M |
| Capital expenditures | 0.00M | 0.01M | 0.03M | 0.02M | 0.01M |
| Change in working capital | -0.66M | 0.85M | 0.00M | 0.11M | -1.87M |
| Stock based compensation | 0.01M | 0.00M | 0.33M | 2.01M | - |
| Other non cash items | - | - | - | - | 1.16M |
| Free cash flow | -4.83M | -12.32M | -6.17M | -5.74M | -10.88M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| LADX LadRx Corporation |
- -% |
0.00 | 4.29 | - | 34.48 | 0.51 | 0.61 |
| NVO Novo Nordisk A/S |
-1.06 2.73% |
37.81 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-5.64 1.08% |
515.02 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
- -% |
920.69 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
LadRx Corporation, a biopharmaceutical company, engages in research and development of chemotherapeutic drugs for solid tumors. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer. Further, the company's Linker Activated Drug Release technology platform consists of an organic backbone, as well as develops albumin companion diagnostic to identify patients with cancer. The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.
11726 San Vicente Boulevard, Los Angeles, CA, United States, 90049
310 826 5648
3
| Name | Title | Year Born |
|---|---|---|
| Mr. John Y. Caloz | CFO, Treasurer & Sr. VP | 1952 |
| Dr. Stephen Snowdy Ph.D. | Chief Exec. Officer | 1970 |
| Molly Carey Poarch | Global & U.S. Head of Corp. Communications | NA |
| Ms. Molly Painter | Pres of USA and Head of Launch & Commercial Operations | 1976 |
| Terri Stevens | Chief Bus. Officer | NA |
| Ms. Cristina Newman | Corp. Sec. | NA |
| Dr. Felix Kratz Ph.D. | Sr. VP, Drug Devel. | 1963 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.